Why do inhibitors arise in patients with haemophilia A?
C. R. M. Hay,
C. R. M. Hay
University Department of Haematology, Manchester Royal Infirmary
Search for more papers by this authorC. R. M. Hay,
C. R. M. Hay
University Department of Haematology, Manchester Royal Infirmary
Search for more papers by this authorDr C. R. M. Hay, University Department of Haematology, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL. e-mail: [email protected]
References
- 1 Addiego, J., Kasper, C.K., Abildgaard, C., Hilgartner, M., Lusher, J., Glader, B. & Aledort, L. (1993) Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet, 342, 462–464.DOI: 10.1016/0140-6736(93)91593-B
- 2 Alper, C.A.A., Raum, L.M., Awdeh, Z.L., Shapiro, S.S. & Yunis, E.J. (1984) Major histocompatibility complex (MHC)-linked complement alleles as markers for the development of anti-factor VIII in hemophiliacs. Progress in Clinical Biological Research, 150, 141–142.
- 3 Aly, A.M., Aledort, L.M., Lee, T.D. & Hoyer, L.W. (1990) Histocompatibility antigen patterns in haemophilic patients with factor VIII antibodies. British Journal of Haematology, 76, 238–241.
- 4 Antonarakis, S.E., and a consortium of international authors (1995) Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood, 86, 2206–2212.
- 5 Bidichandani, S.I., Lanyon, W.G., Shiach, C.R., Lowe, G.D.O. & Connor, J.M. (1995) Detection of mutations in ectopic factor VIII transcripts from nine haemophilia patients and the correlation with phenotype. Human Genetics, 95, 531–538.
- 6 Bray, G.L., Gomperts, E.D., Courter, S., Gruppo, R., Gordon, E.M., Manco-Johnson, M., Shapiro, A., Scheibel, E., White, G., Lee, M., and the Recombinate study group (1994) A multicenter study of recombinant factor VIII (Recombinate): safety efficacy and inhibitor risk in previously untreated patients with hemophilia A. Blood, 83, 2428–2435.
- 7 Briet, E., Rosendaal, F.R., Kreuz, W., Rasi, V., Peerlinck, K., Vermylen, J., Ljung, R., Rocino, A., Addiego, J., Lorenzo, J.I. & Pabinger, I. (1994) High titre inhibitors in severe haemophilia A: a meta-analysis based on eight long-term follow-up studies concerning inhibitors associated with crude or intermediate purity factor VIII products. Thrombosis and Haemostasis, 72, 162–164.
- 8 Cibotti, R., Kanellopous, J.M., Cabaniols, J-P., Halle-Paneko, O., Kosmatopoulos, K., Sercarz, E. & Kourilsky, P. (1992) Tolerance to a self-protein involves its immunodominant involves its immunodominant but does not involve its subdominant determinants. Proceedings of the National Academy of Sciences of the United States of America, 89, 416–424.
- 9 Colvin, B.T., Hay, C.R.M., Hill, F.G.H. & Preston, F.E. (1995) The incidence of factor VIII inhibitors in the United Kingdom, 1990–1993. British Journal of Haematology, 89, 908–910.
- 10 De Biasi, R., Rocino, A., Papa, M.L., Salerno, E., Mastrullo, L. & De Biasi, D. (1994) Incidence of factor VIII inhibitor development in haemophilia A patients treated with less pure plasma-derived concentrates. Thrombosis and Haemostasis, 71, 544–547.
- 11 Ehrenforth, S., Kreutz, W., Scharrer, I., Linde, R., Funk, M. & Gungor, T. (1992) Incidence of development of factor VIII and IX inhibitors in haemophiliacs. Lancet, 339, 594–598.DOI: 10.1016/0140-6736(92)90874-3
- 12 Fijnvandraat, K., Patrick, H.N.C., Turenhout, E.A.M., Ten Cate, J.W., Van Mourik, J.A., Mertens, K., Peters, M. & Voorberg, J. (1998) A human alloantibody interferes with binding of factor IXa to the factor VIII light chain. Blood, 91, 2347–2352.
- 13 Fijnvandraat, K., Turenhout, E.A.M., Van Den Brink, E.N., Ten Cate, J.W., Mouril, J.A., Peters, M. & Voorberg, J. (1997) The missense mutation Arg593-Cys is related to antibody formation in a patient with mild hemophilia A. Blood, 89, 4371–4377.
- 14 Frommel, D., Allain, J.P., Saint-Paul, E., Bosser, C., Noel, B., Mannucci, P.M., Pannicucci, F., Blomback, M., Prou-Wartelle, J. & Muller, J.Y. (1981) HLA antigens and factor VIII antibody in classic haemophilia. Thrombosis and Haemostasis, 46, 687–689.
- 15 Gilles, J.G., Peerlinck, K., Arnout, J., Vermylen, J. & Saint-Remy, J.-M.R. (1997) Restricted epitope specificity of anti-FVIII antibodies that appeared during a recent outbreak of inhibitors. Thrombosis and Haemostasis, 77, 938–943.
- 16 Hay, C.R.M., Colvin, B.T., Ludlam, C.A., Hill, F.G.H. & Preston, F.E. (1996) Recommendations for the treatment of factor VIII inhibitors: from the UK Haemophilia Centre Directors Organisation Inhibitor Working Party. Blood Coagulation and Fibrinolysis, 7, 134–138.
- 17 Hay, C.R.M., Ludlam, C.A., Colvin, B.T., Hill, F.G.H., Preston, F.E., on behalf of the UK Haemophilia Centre Directors Organisation Inhibitor Working Party, and also Berntorp, E., Mauser-Bunschoten, E.P., Fijnvandraat, K., Kasper, C.K., White, G. III, Mannucci, P.M. & Santagostino, E. (1998) Factor VIII inhibitors in mild and moderate severity haemophilia A. Thrombosis and Haemostasis, 79, 762–766.
- 18 Hay, C.R.M., Ollier, W., Pepper, L., Cumming, A., Keeney, S., Goodeve, A.C., Colvin, B.T., Hill, F.G.H., Preston, F.E. & Peake, I.R. (1997) HLA Class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. Thrombosis and Haemostasis, 77, 234–237.
- 19 Healey, J.F., Lubin, I.M., Nakai, H., Saenko, E.L. & Hoyer, L.W. (1995) Residues 485–508 contain a major determinant of the inhibitory epitope of the A2 domain of human factor VIII. Journal of Biological Chemistry, 270, 14505–14509.DOI: 10.1074/jbc.270.24.14505
- 20 Hoyer, I.W. (1995) Why do so many haemophilia A patients develop an inhibitor? British Journal of Haematology, 90, 498–501.
- 21 Josic, D., Stadler, M., Buchacher, A., Pock, K. & Schwinn, H. (1997) Degradation products of factor VIII which can lead to increased immunogenicity. Thrombosis and Haemostasis, 78, (Suppl.), 576.
- 22 Kemball-Cook, G. & Tuddenham, E.G.D. (1997) The factor VIII mutation database on the World Wide Web: the haemophilia A mutation, search, test and resource site HAMSTeRS update (version 3.0). Nucleic Acids Research, 25, 128–132. (Also httph://146.179.66.63/usr/www/webpages/main.dir/copywrit.htm.)DOI: 10.1093/nar/25.1.128
- 23 Laub, R., Di Giambattista, M., Fondu, P., Brackmann, H.H., Lenk, H. & Scandella, D. (1997) Restricted epitope specificity of factor VIII inhibitors which appeared in previously treated haemophiliacs after infusion of OCTAVI SD plus. Thrombosis and Haemostasis, 78, (Suppl.), 590.
- 24 Lippert, L.E., McFisher, A. & Shook, L.B. (1990) Relationship of major histocompatibility complex class II genes to inhibitor antibody formation in haemophilia A. Thrombosis and Haemostasis, 91, 564–568.
- 25 Lipton, R.A. (1994) The economics of factor VIII inhibitor treatment. Seminars in Haematology, 31, 41–43.
- 26 Lusher, J.M., Arkin, S., Abildgaard, C.F. & Schwarz, R.S. (1993) Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. New England Journal of Medicine, 328, 453–459.DOI: 10.1056/NEJM199302183280701
- 27 Mauser-Bunschoten, E.P., Rosendaal, F.R., Niewenhuis, H.K., Roosendaal, G., Briet, E. & Van Den Berg, H.M. (1994) Clinical course of factor VIII inhibitors developed after exposure to a pasteurised Dutch concentrate compared to classic inhibitors in haemophilia A. Thrombosis and Haemostasis, 71, 703–706.
- 28 Mayr, W.R., Lechner, K., Neissner, H. & Papinger-Fashing, I. (1984) HLA-DR and factor VIII antibodies in hemophilia A. Thrombosis and Haemostasis, 51, 293–296.
- 29 McMillan, C.W., Shapiro, S.S., Whitehurst, D., Hoyer, L.W., Rao, V. & Lazerson, J. (1988) The natural history of factor VIII inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on initial development of factor VIII inhibitors. Blood, 71, 344–351.
- 30 Oldenburg, J., Picard, J.K., Schwaab, R., Brackman, H.H., Tuddenham, E.G.D. & Simpson, E. (1997) HLA genotype of patients with severe haemophilia due to intron 22 inversion with and without inhibitors of factor VIII. Thrombosis and Haemostasis, 77, 238–242.
- 31 Papasteriades, C., Varla, M., Ecomidou, J., Mitsouli, C., Louiso, U.K., Mandalaki, T., Roumelitou, A. & Papevangelou, G. (1986) High frequency of HLADR5 in Greek patients with hemophilia A and hemophilia B. Tissue Antigens, 28, 84–87.
- 32 Peerlinck, K., Arnout, J., Di Giambattista, M., Gilles, J.G., Laub, R., Jacquemin, M., Saint-Remy, J.M.R. & Vermylen, J. (1997) Factor VIII inhibitors in previously treated haemophilia A patients with a double virus inactivated plasma derived concentrate. Thrombosis and Haemostasis, 77, 80–86.
- 33 Peerlinck, K., Arnout, J., Gilles, J.G., Saint-Remy, J.G. & Vermylen, J. (1993 a) A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate-purity pasteurised factor VIII concentrate. Thrombosis and Haemostasis, 69, 115–118.
- 34 Peerlinck, K., Rosendaal, F.R. & Vermylen, L. (1993 b) Incidence of inhibitor development in a group of young hemophilia A patients treated with lyophylised cryoprecipitate. Blood, 81, 3332–3335.
- 35 Pienman, W.C., Deutz-Terlouw, P.P., Reitsma, P.H. & Briet, E. (1995) Screening for mutations in haemophilia A patients by mutiplex PCR-SSCP, Southern blotting and RNA analysis: detection of a genetic abnormality in the factor VIII gene in 30 out of 35 patients. British Journal of Haematology, 90, 442–449.
- 36 Prescott, R., Nakai, H., Saenko, E.L., Scharrer, I., Nilsson, I.M., Humphries, J.E., Hurst, D., Bray, G. & Scandella, D. (1997) The inhibitor antibody response is more complex in hemophilia A patients than in most non-hemophiliacs with factor VIII autoantibodies. Blood, 89, 3663–3671.
- 37 Rasi, V. & Ikkala, E. (1990) Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcome. British Journal of Haematology, 76, 369–371.
- 38 Rivard, G.E. & Vicks, S. (1994) Economics of inhibitor treatment in Canada. Seminars in Haematology, 31, 41–43.
- 39 Rizza, C.R. & Spooner, R.G.D. (1983) Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976–80: report on behalf of the Directors of Haemophilia Centres in the United Kingdom. British Medical Journal, 286, 929–932.
- 40 Rosendaal, F.R. (1997) Factor VIII inhibitors on a SD-treated and pasteurised concentrate associated with specific batches and batch characteristics. Thrombosis and Haemostasis, 78, (Suppl.), 590.
- 41 Rosendaal, F.R., Niewenhuis, H.K., Van Den Berg, H.M., Heijboer, H., Mauser-Bunschoten, E.P., Van Der Meer, J., Smit, C., Strengers, P.F.W., Briet, E., and the Dutch Hemophilia Study Group (1993) A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands. Blood, 81, 2180–2186.
- 42 Santagostino, E., Gringeri, A., Tagliavacca, L. & Mannucci, P.M. (1995) Inhibitors to factor VIII in a family with mild hemophilia: molecular characterisation and response to factor VIII and desmopressin. Thrombosis and Haemostasis, 74, 619–621.
- 43 Sawamoto, Y., Prescott, R., Zhong, D., Saenko, E.L., Mauser-Bunschotten, E.P., Peerlinck, K., Van den Berg, H.M. & Scandella, D. (1998) Dominant C2 domain epitope specificity of inhibitor antibodies elicited by a heat pasteurised product, factor VIII CPS-P, in previously treated hemophilia A patients without inhibitors. Thrombosis and Haemostasis, 79, 62–68.
- 44 Scandella, D., Gilbert, G.E., Shima, M., Eagleson, C., Felch, M., Prescott, R., Rajalakshimi, K.J. & Saenko, E. (1995) Some factor VIII inhibitor antibodies recognise a common epitope corresponding to C2 domain amino acids 2248–2312 which overlap a phospholipid binding site. Blood, 86, 1811–1617.
- 45 Scandella, D., Mattingly, M. & Prescot, R. (1993) A recombinant factor VIII A2 domain polypeptide quantitatively neutralises human inhibitor antibodies that bind to A2. Blood, 82, 1767–1775.
- 46 Scandella, D., Timmons, L., Mattingly, M., Trabold, N. & Hoyer, L.W. (1992) A soluble recombinant factro VIII fragment containing the A2 domain binds to some human anti-factor VIII antibodies that are not detected by immunoblotting. Thrombosis and Haemostasis, 67, 665–669.
- 47 Schimpf, K., Schwarz, H.P. & Kunschak, M. (1995) Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex. Thrombosis and Haemostasis, 73, 553–554.
- 48 Schwaab, R., Brackmann, H.H., Meyer, C., Seehafer, J., Kirchgesser, M., Hack, A., Olek, K., Tuddenham, E.G.D. & Oldenberg, J. (1995 a) Haemophilia A: mutation type determines risk of inhibitor formation. Thrombosis and Haemostasis, 74, 1402–1406.
- 49 Schwaab, R., Oldenburg, J., Schwaab, U., Johnson, D.J.D., Schmidt, W., Olek, K., Brackmann, H.H. & Tuddenham, E.G.D. (1995 b) Characterisation of mutations within factor VIII gene of 73 unrelated mild and moderate haemophiliacs. British Journal of Haematology, 90, 442–447.
- 50 Schwaab, R., Oldenburg, J., Tuddenham, E.G.D., Brackmann, H.H. & Olek, K. (1993) Mutations in haemophilia A. British Journal of Haematology, 83, 450–455.
- 51 Schwarzinger, I., Pabbinger, I., Korninger, C., Haschke, F., Kundi, M., Neissner, H. & Lechner, J. (1987) Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates. American Journal of Haematology, 24, 241–245.
- 52 Sultan, Y., and the French Hemophilia Study Group (1992) Prevalence of inhibitors in a population of 3435 hemophilia patients in France. Thrombosis and Haemostasis, 67, 600–602.
- 53 Thompson, A.R., Murphy, M.E.P., Liu, M., Saenko, E.L., Healey, J.F., Lollar, P. & Scandella, D. (1997) Loss of tolerance to exogenous and endogenous factor VIII in a mild hemophilia A patient with an Arg593 to Cys mutation. Blood, 90, 1902–1910.
- 54 Tuddenham, E.G.D. & McVey, J.H. (1998) The genetic basis of inhibitor development in haemophilia A. Haemophilia, 4, 543–545.DOI: 10.1046/j.1365-2516.1998.440543.x
- 55 Tuddenham, E.G.D., Schwaab, R., Seehafer, J., Millar, D.S., Gitcher, J., Higuchi, M., Bidichandani, S., Connor, J.M., Hoyer, L.W., Yoshioka, A., Peake, I.R., Olek, K., Kazazian, H.H., Lavergne, J.M., Giannelli, F., Antoniarakis, S.E. & Cooper, D.N. (1994) Haemophilia A: database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene, second edition. Nucleic Acids Research, 22, 3511–3533.
- 56 Yee, T.T., Williams, M.D., Hill, F.G.H., Lee, C.A. & Pasi, J.K. (1997) Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product. Thrombosis and Haemostasis, 78, 1027–1029.
Citing Literature
